Search results for: Multi-Indication Medicines

Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies

1 June 2021

…report, OHE authors present key considerations for developing early access schemes for single-administration therapies. In our report, OHE authors review the existing routes for early access to medicines and discuss…

Lung Cancer’s Biggest Test: How Can We Mobilise NGS Testing to Transform Lung Cancer Care?

7 December 2023, 12:00am

…access to personalized medicines and combination medicines.  She has expertise in market access and HTA, leading multiple submissions to NICE and the Scottish Medicines Consortium. Professor Mike Drummond | Professor…

OHE at ISPOR’s 20th Annual European Congress: Presentations

…Health Economics   Martina was also part of the faculty of the short course on “Using Multi-Criteria Decision Analysis (MCDA) in Health Care Decision Making: Approaches & Applications”. Her part…

Can We Really Compare and Aggregate Patient-reported Outcomes Between People and Settings?

11 April 2019

…paper is authored by Nancy Devlin (University of Melbourne), Paula Lorgelly (King’s College London), and Mike Herdman (OHE). Clinical trials are increasingly being conducted across multiple countries and regions. The…

Efficiency Measurement in Primary Care: Time to Overcome the Challenges and Achieve Some Gains

10 March 2021

…consultations provided, surgical procedures performed, or medicines prescribed – tells us nothing about the value of that output in terms of health, such as the impact on length or quality…

Recently Published: MCDA to Elicit Stakeholders’ Preferences: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma

20 December 2016

…Kent, A. & Hutchings, A. 2013. A pilot study of multicriteria decision analysis for valuing orphan medicines. Value Health, 16, 1163-9. For more information please contact Martina Garau at OHE….

OHE’s submission for the DHSC’s next 10 years of planning

9 December 2024

…included in the 10-Year Health Plan and why? As we are faced with an ageing population and the increasing prevalence of multiple, comorbid illnesses, it’s all the more important to…

OHE Achievements in 2018

27 December 2018

…research projects on new reimbursement models.  One, funded by IQVIA, considered innovative payment models including multi-indication pricing as an alternative to single prices. Collaborators included Richard Sullivan (King’s College London)….

Amanda Cole

30 May 2014

…drug development innovations require new reimbursement models, especially for multi-indication therapies, precision medicine, and gene therapies. She is keen to advance a research agenda for how real-world evidence can improve…